Ascelia Pharma: Improving cancer contrast - ABG

Alternative MRI contrast agent for frail cancer patients
Ph 3 finished and ready for FDA filing
Initiating coverage, fair value range of SEK 2.6-5.1


Addressing unmet medical needs in oncology

We initiate coverage on Ascelia Pharma, a Swedish biotech company focused on the development of novel drugs to detect and treat cancer. The lead product is Orviglance, a novel manganese-based magnetic resonance imaging (MRI) contrast agent developed for the detection of liver tumours in cancer patients with impaired kidney function. The drug passed Ph 3 successfully in 2024, and is currently in preparations for a US FDA filing by mid-'25. The company's second Ph 2-ready product Oncoral is an improved formulation of the chemotherapy irinotecan for the treatment of gastric cancer.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/ascelia-pharma/Equity-research/2025/4/ascelia-pharma---improving-cancer-contrast/